Drug Innovation
Commentary
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Commentary
To help patients save money, Congress needs to tackle the middlemen in health care
As a Republican-controlled House of Representatives with a small majority opens for business in January, one member has especially big ideas for saving patients money on prescription drug costs — and the research to back it up. A year ago, Rep. James Comer (R-KY) released a comprehensive report on the ...
Commentary
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
Blog
What do Ticketmaster and Pharmacy Benefit Managers have in common?
Popular American singer and songwriter, Taylor Swift, released her newest album ‘Midnights’ in October. The album quickly became the most-streamed album in 24 hours on Spotify, with 184.6 million streams, according to Guinness World Records. Following the release, the artist sought to work with Ticketmaster, a company who arguably has ...
Commentary
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Commentary
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Commentary
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
Commentary
Simple Fix for Healthcare: Give Patients More Responsibility
Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
Drug Innovation
NEW BRIEF: Promoting Transparency and Competition in the Drug Market
DOWNLOAD THE BRIEF BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include: fostering a ...
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
To help patients save money, Congress needs to tackle the middlemen in health care
As a Republican-controlled House of Representatives with a small majority opens for business in January, one member has especially big ideas for saving patients money on prescription drug costs — and the research to back it up. A year ago, Rep. James Comer (R-KY) released a comprehensive report on the ...
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
What do Ticketmaster and Pharmacy Benefit Managers have in common?
Popular American singer and songwriter, Taylor Swift, released her newest album ‘Midnights’ in October. The album quickly became the most-streamed album in 24 hours on Spotify, with 184.6 million streams, according to Guinness World Records. Following the release, the artist sought to work with Ticketmaster, a company who arguably has ...
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
Simple Fix for Healthcare: Give Patients More Responsibility
Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
NEW BRIEF: Promoting Transparency and Competition in the Drug Market
DOWNLOAD THE BRIEF BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include: fostering a ...
